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Introduction
Results of the IMPRESSION trial published in 2015 proved that morphine use in 
patients with acute coronary syndromes (ACS) is associated with an undesirable impact on 
pharmacokinetics (PK) and pharmacodynamics (PD) of ticagrelor [1]. Several other studies of
the antiplatelet activity of all oral P2Y12 receptor inhibitors, ticagrelor, prasugrel and 
clopidogrel, also reported noticeable impairment of their antiaggregatory effect when 
morphine was co-administered in the course of ACS or in healthy volunteers [2–5]. This 
negative effect may be substantially increased by medical approaches such as mild therapeutic
hypothermia in patients presenting with out of hospital cardiac arrest [6]. Based on available 
data, the latest European Society of Cardiology (ESC) guidelines on the management of acute 
ST-segment elevation myocardial infarction patients reduced the class of recommendation of 
titrated opioid use to IIa [7]. Despite this, morphine is still a standard analgesic treatment in 
ACS patients and it should not be routinely withdrawn [8–10]. Based on available research, 
morphine, acting via µ-opioid receptors, was found to inhibit gastrointestinal motility or 
induce adverse effects such as nausea or vomiting [11]. Therefore, an inevitable consequence 
of those clinical trials was to establish an approach which would maximally allow  
overcoming the so-called “morphine-effect” as efficient pretreatment with P2Y12 inhibitors 
being proven to be beneficial [12]. Crushing P2Y12 receptor inhibitors tablets was consistently
found to be successful in terms of improvement of PK/PD of these medications [13–15]. As 
was found in one of our previous trials, the addition of metoclopramide, which may to some 
extent positively influence the PK/PD of ticagrelor, but such an approach definitely cannot be 
considered as a method of overcoming the “morphine effect” [16]. On the other hand, the 
addition of naloxone was not beneficial in terms of PK/PD profile of ticagrelor [17]. Also, 
switching from morphine to another opioid analgesic, fentanyl, did not allow to waive the 
negative morphine effect in the PACIFY trial [18]. It was decided to design a clinical study 
aiming to evaluate the impact of methoxyflurane on the PD of ticagrelor in patients diagnosed
with unstable angina pectoris (UA). Methoxyflurane is an inhaled anesthetic, registered in 
Poland in emergency medicine for pain alleviation in trauma patients. The drug was widely 
used in the 1960s to induce general anesthesia, however its clinical utility was reduced with 
the development of novel anesthetic agents. Taking into account its different mechanism of 
action, it can be presumed that, contrary to morphine, no respiratory depression should be 
observed as well as no attenuation or delay of antiaggregatory effect of ticagrelor should 
occur, as no interaction with the µ-receptor in the gastrointestinal tract is related to activity of 
methoxyflurane. 
Methods
This study was designed as a phase IV, open-label, randomized, multi-center clinical 
trial. The protocol of the study was approved by the Ethics Committee of The Nicolaus 
Copernicus University and received approval number KB 37/2020. All UA patients admitted 
to the study centers will be screened for eligibility. UA is defined as myocardial ischemia 
symptoms in class III or IV according to the Canadian Cardiovascular Society (CCS) with 
troponin serum concentration within the reference range accompanied with newly diagnosed 
regional impairment of left ventricle contraction in echocardiography and/or acute signs of 
ischemia in electrocardiogram at admission. Major inclusion criteria include males and non-
pregnant females, aged 18–80, diagnosed with UA, planned for coronary angiography and 
percutaneous coronary intervention if required, and graded < 140 points in GRACE score. 
Among the exclusion criteria current use of oral anticoagulants, P2Y12 receptor inhibitors, 
heparin, history of coagulation disorders, intracranial bleeding or recent gastrointestinal 
hemorrhage as well as clinically-significant bradycardia or 2nd/3rd degree atrioventricular 
block are also to be noted. The complete list of study inclusion and exclusion criteria is 
presented in Table 1. All study-related procedures will be conducted in full accordance with 
The Declaration of Helsinki and Good Clinical Practice regulations after the obtainment of 
written informed consent from each enrolled participant. Patients will be randomized in a 
1:1:1 ratio into the study arms as follows: 1) 180 mg ticagrelor (2 integral tablets of 90 mg 
ticagrelor) followed by 3 mg inhaled methoxyflurane methoxyflurane (3 mg is a dose 
included in a single-use dispenser, the patient will be advised to inhale the drug for 15 
minutes between time-points: baseline and 15 minutes post ticagrelor loading dose [LD]), 2) 
180 mg ticagrelor followed by 5 mg intravenous morphine, 3) 180 mg ticagrelor alone. Each 
study participant will undergo pharmacodynamic assessment at time points 0 (prior to the 
administration of ticagrelor LD) and at 15, 30, 45, 60, 120, 180, 240, 360 minutes after the 
LD. Platelet activity will be assessed using multiple electrode aggregometry (MEA). 
Pharmacokinetic assessment of ticagrelor and its active metabolite will be performed at each 
time point. The schematic presentation of the patients’ flow through the study is presented in 
Figure 1. 
Sample size calculation
Taking into account previous studies conducted in the Department of Cardiology in 
Bydgoszcz, Poland, which aimed to evaluate pharmacokinetics and pharmacodynamics of 
ticagrelor in patients treated for UA, as well as the fact that no similar clinical studies were 
completed to date, a group of 75 patients, 25 for each study arm was estimated as sufficient 
for the obtainment of significant differences between the measured parameters. 
Blood sample collection
Directly after randomization, all study participants will undergo blood sampling 
collection (time point 0), which will be followed by the administration of ticagrelor LD and 
analgesics according to the study protocol. The remaining blood samples will be obtained at 
the following time points: 15, 30, 45, 60, 120, 180, 240, 360 minutes after ticagrelor LD by 
nurses employed in each study site. The use of vascular catheters is planned, which is meant 
to minimize the potential patient discomfort associated with blood sample obtainment. The 
procedure will be supervised by doctors responsible for the recruitment of participants.  
Endpoints
The primary endpoint of the trial is the mean platelet reactivity between the study 
arms, assessed using the Multiplate Analyzer within the time frame of 6 hours following 
ticagrelor LD. 
Secondary endpoints of the study were defined as (1) the percentage of patients with 
high platelet reactivity throughout the study period and (2) mean time to achieve platelet 
reactivity below the threshold for HPR (3) area under the plasma concentration-time curve for
ticagrelor and its active metabolite between the study arms. 
Pharmacodynamics and pharmacokinetics assessment
The evaluation of platelet reactivity is planned for all study participants at the 
aforementioned study time points using MEA. Platelet reactivity testing will be performed in 
the internal research laboratories by investigators employed at each center conducting the 
study-related procedures. 
According to the study protocol, the assessment of pharmacokinetic parameters of 
ticagrelor and its active metabolite for all enrolled patients will be performed at each study 
time point. All samples will be evaluated in the Study Central Lab.
Safety assessment
Each study participant will be treated according to the latest ESC guidelines for the 
management of patients presenting with ACS, which will include coronary angiography and 
percutaneous coronary intervention, if necessary. All enrolled patients will receive a complete 
pharmacological treatment for ACS comprised of dual antiplatelet therapy, statin, beta-blocker
and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, unless 
contraindicated. Only subjects with < 140 points according to GRACE score will be enrolled, 
which will allow the investigators to postpone coronary angiography for at least 6 hours after 
the randomization; the time which is required to complete the blood sampling scheme. In case
of any episode of severe pain with no improvement after the baseline administration of 
analgesic agents according to randomization, an additional dose of 3 mg of inhaled 
methoxyflurane or 5 mg of intravenous morphine will be given appropriately. The evaluation 
of drug efficacy in such cases will be performed every 3 minutes. However, any case of 
unbearable persisting chest pain will result in the premature termination of the patient’s 
participation in the trial. The patient will undergo immediate coronary angiography and will 
receive symptoms-driven analgesia. Any adverse effects of administered medications, 
including abnormalities in patients’ vital signs, blood pressure, heart rate, respiratory rate, 
arrhythmias, dyspnea as well as deterioration of kidney or hepatic function based on 
laboratory tests performed routinely during hospitalization, will be recorded and treated 
appropriately as to the event.
Discussion
Based on the results of several worldwide clinical trials mentioned above in this 
manuscript, it has become clear that morphine use is associated with undesirable effects on 
PK and PD of antiplatelet agents. Nevertheless, none of the methods of overcoming the so-
called “morphine effect” including crushing P2Y12 receptor inhibitors tablets, sublingual 
administration of those agents or co-administration of either metoclopramide or naloxone 
turned out efficient enough to ensure rapid platelet inhibition which is crucial to succeed in 
the treatment of ACS. Moreover, changing morphine to another opioid agent, fentanyl, also 
showed no superiority in terms of improvement of PK/PD profile of ticagrelor, which may be 
explained by the class effect of those drugs. To date, the clinical utility of methoxyflurane in 
ACS patients has never been examined. It was decided to exclusively select UA patients so as 
make this trial maximally comparable to previously conducted studies aiming to evaluate the 
influence of various ticagrelor administration strategies on its PK/PD profile [13, 16, 17]. 
However, taking into account differences in the mechanism of action of methoxyflurane and 
opioids, no impairment of ticagrelor pharmacodynamic profile may be expected. If such a 
thesis is confirmed, it may lead to a major breakthrough in terms of effective antiplatelet 
treatment of patients presenting with ACS. 
Trial status
The study was registered on clinicaltrials.gov and received the registration number 
NCT04442919, date of registration 27 June 2020. It is currently recruiting participants. 
https://clinicaltrials.gov/ct2/show/NCT04442919. 
Ethics approval and consent to participate
The protocol of the study was approved by the Ethics Committee of The Nicolaus 
Copernicus University and received approval number KB 37/2020.
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Table 1. A complete list of inclusion and exclusion criteria in the study.
*All criteria must be met; **None of the criteria can be met
NYHA — New York Heart association; PCI — percutaneous coronary intervention
Inclusion criteria*
Provision of informed consent prior to any study specific procedures
Diagnosis of unstable angina
Male or non-pregnant female, aged 18–80 years 
Provision of informed consent for angiography and PCI
GRACE score < 140 points
Exclusion criteria**
Treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before the study enrollment
Current treatment with morphine or any opioid “mi” receptor agonist 
Hypersensitivity to ticagrelor
Current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin
Active bleeding
History of intracranial hemorrhage
Recent gastrointestinal bleeding (within 30 days)
History of coagulation disorders
Platelet count less than < 100 × 10^3/µl
Hemoglobin concentration less than 10.0 g/dl
History of moderate or severe hepatic impairment
History of major surgery or severe trauma (within 3 months)
Risk of bradycardic events as judged by the investigator
Second- or third-degree atrioventricular block during screening for eligibility
History of asthma or severe chronic obstructive pulmonary disease
Kidney disease requiring dialysis
Manifest infection or inflammatory state
Killip class III or IV during screening for eligibility
Respiratory failure
History of severe chronic heart failure (NYHA class III or IV)
Concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, 
nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir) or strong CYP3A inducers (rifampicin, phenytoin, 
carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment
Body weight below 50 kg
Figure 1. The patients’ flow through the study; MEA — multiple electrode aggregometry.
eligibility screening
Randomization
Diagnosis of unstable angina 
pectoris
180 mg ticagrelor + 3 mg 
inhaled methoxyflurane
180 mg ticagrelor + 5 mg 
intraveous morphine
Pharmacodynamics (MEA + VerifyNow) and Pharmacokinetics 
assessment
180 mg ticagrelor
